Company Overview
Snapshot
Founded in May 2018, Healios Biologics is a pre-funding stage company operating in the Health Tech & Life Sciences sector. The company's status indicates it ceased operations in May 2022. A key milestone for the company was the development of High Content Analysis for the diagnosis and prognosis of rare diseases in May 2018.
Business overview
Healios Biologics operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Test Diagnostics & Screening. The company's core technology involves High Content Analysis for the diagnosis and prognosis of rare diseases, indicating a specialization in advanced diagnostic methods within the pharmaceutical and diagnostics categories.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant technological development by Healios Biologics?
- In May 2018, Healios Biologics developed High Content Analysis technology for the diagnosis and prognosis of rare diseases, focusing on diagnostics within the pharmaceutical sector.
- When was Healios Biologics founded?
- Healios Biologics was founded in May 2018.
- In which primary sector does Healios Biologics operate?
- Healios Biologics operates in the Health Tech & Life Sciences sector.
- What is the current operational status of Healios Biologics?
- Healios Biologics is currently non-active and ceased operations in May 2022.
- What is Healios Biologics' funding stage?
- Healios Biologics is currently in the Pre-Funding stage, indicating it has not yet raised external capital.